Replies to post #41997 on ORIONS Money Stocks

[thekrup]

OSCI- pr for approval in Europe for their drug is imminent.

Regulatory Filing for FACTIVE Tablets Submitted in Europe
Oscient Pharmaceuticals' partner, Menarini Group, seeks marketing approval for fluoroquinolone antibiotic

WALTHAM, Mass.--(BUSINESS WIRE)--May 7, 2008--Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) commercialization partner for FACTIVE(R) (gemifloxacin mesylate) tablets, Menarini Group, a leading European pharmaceutical company based in Italy, has submitted a regulatory filing seeking approval of FACTIVE in Europe. Menarini, with broad sales and marketing coverage throughout Europe and expertise in research and clinical development, has the fourth largest pharmaceutical sales force in Europe and is second largest in terms of calls to primary care physicians.

"Menarini's pursuit of marketing approval for FACTIVE in Europe is an important step in our commercialization plan for FACTIVE in our licensed territories," stated Steven M. Rauscher, President and Chief Executive Officer of Oscient Pharmaceuticals. "Menarini is a strong, experienced partner, and we look forward to working together to build the FACTIVE brand in Europe."

Menarini is seeking approval of FACTIVE for the treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis and acute bacterial sinusitis. The regulatory review time in Europe is approximately 12 months.

Oscient granted commercialization rights to Menarini for FACTIVE in Europe last year. The oral antibiotic market in Europe is estimated at $5 billion, with France, Germany, Italy and Spain representing the largest markets. Oscient licenses the rights to commercialize FACTIVE in North America and Europe from LG Life Sciences. In 2006, Oscient forged partnerships for the commercialization of the drug in Mexico and Canada.

About Menarini

The Menarini Group is a privately owned pharmaceutical company headquartered in Florence, Italy. Menarini employs approximately 13,000 people, with a strong presence in Western and Eastern Europe, Asia and Central America. In addition to advancing products through internal research and development, Menarini has strong experience in seeking regulatory approval and marketing in-licensed products from a large number of pharmaceutical companies. In 2007, the Menarini Group generated revenue of 2.5 billion euros.

[Duke4U]

Funny that you mentioned that because I am looking at level 2 right now and there is huge inventory sitting on the ASK and The bids are a whole .01 above the ASK... I wouldnt go near it right now, I think the MM is trying to dump some shares